Published in Mol Biol Evol on May 28, 2011
Polymorphic sites at the 3' untranslated region of the HLA-G gene are associated with differential hla-g soluble levels in the Brazilian and French population. PLoS One (2013) 0.99
The dual role of HLA-G in cancer. J Immunol Res (2014) 0.94
Role of non-classical MHC class I molecules in cancer immunosuppression. Oncoimmunology (2013) 0.92
Transcriptional and posttranscriptional regulations of the HLA-G gene. J Immunol Res (2014) 0.92
Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study. Am J Pathol (2012) 0.89
Worldwide genetic variation at the 3' untranslated region of the HLA-G gene: balancing selection influencing genetic diversity. Genes Immun (2013) 0.86
Insights into HLA-G Genetics Provided by Worldwide Haplotype Diversity. Front Immunol (2014) 0.85
Controlling the Immunological Crosstalk during Conception and Pregnancy: HLA-G in Reproduction. Front Immunol (2014) 0.84
Balancing immunity and tolerance: genetic footprint of natural selection in the transcriptional regulatory region of HLA-G. Genes Immun (2014) 0.82
HLA Class Ib Molecules and Immune Cells in Pregnancy and Preeclampsia. Front Immunol (2014) 0.81
HLA-G UTR haplotype conservation in the Malian population: association with soluble HLA-G. PLoS One (2013) 0.80
Polymorphic variants in exon 8 at the 3' UTR of the HLA-G gene are associated with septic shock in critically ill patients. Crit Care (2012) 0.80
HLA-G expression levels influence the tolerogenic activity of human DC-10. Haematologica (2015) 0.80
Some basic aspects of HLA-G biology. J Immunol Res (2014) 0.80
The many faces of human leukocyte antigen-G: relevance to the fate of pregnancy. J Immunol Res (2014) 0.80
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. PLoS One (2015) 0.79
The Role of HLA-G Molecule and HLA-G Gene Polymorphisms in Tumors, Viral Hepatitis, and Parasitic Diseases. Front Immunol (2015) 0.78
Human leukocyte antigen (HLA)-G gene polymorphism in patients with non-small cell lung cancer. Thorac Cancer (2015) 0.78
HLA-G polymorphism (rs16375) and acute rejection in liver transplant recipients. Dis Markers (2014) 0.77
Hypoxia inducible factor-1 mediates the expression of the immune checkpoint HLA-G in glioma cells through hypoxia response element located in exon 2. Oncotarget (2016) 0.76
Association of genetic variants in the 3'UTR of HLA-G with Recurrent Pregnancy Loss. Hum Immunol (2016) 0.76
New evidence for balancing selection at the HLA-G locus in South Amerindians. Genet Mol Biol (2012) 0.76
Case-control study of HLA-G promoter methylation status, HPV infection and cervical neoplasia in Curitiba, Brazil: a pilot analysis. BMC Cancer (2012) 0.76
The +3187A/G HLA-G polymorphic site is associated with polar forms and reactive reaction in leprosy. Mol Genet Genomic Med (2013) 0.76
Impact of HLA-G analysis in prevention, diagnosis and treatment of pathological conditions. World J Methodol (2014) 0.75
Human leucocyte antigen-G (HLA-G) and its murine functional homolog Qa2 in the Trypanosoma cruzi Infection. Mediators Inflamm (2015) 0.75
Association of HLA-A and Non-Classical HLA Class I Alleles. PLoS One (2016) 0.75
Hypoxic Modulation of HLA-G Expression through the Metabolic Sensor HIF-1 in Human Cancer Cells. J Immunol Res (2017) 0.75
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med (2007) 5.84
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 5.80
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood (2006) 4.61
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS (2003) 3.60
The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica (2007) 3.23
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol (2010) 3.09
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol (2010) 2.75
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol (2009) 2.49
Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory‐confirmed secondary attack rates and evidence of asymptomatic infections. Clin Infect Dis (2010) 2.41
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39
Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med (2009) 2.36
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica (2006) 2.12
International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol (2010) 2.09
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica (2006) 1.99
Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS (2008) 1.89
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol (2012) 1.85
Reestablishment of damaged adult motor pathways by grafted embryonic cortical neurons. Nat Neurosci (2007) 1.83
Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2009) 1.82
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. J Clin Oncol (2013) 1.80
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol (2013) 1.79
Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec. J Infect Dis (2011) 1.70
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood (2011) 1.69
Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol (2009) 1.69
Thalidomide for treatment of multiple myeloma: 10 years later. Blood (2008) 1.66
Prosthetic hip joint infection with a Streptococcus agalactiae isolate not susceptible to penicillin G and ceftriaxone. J Antimicrob Chemother (2009) 1.65
Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol (2012) 1.60
Performance of an agar dilution method and a Vitek 2 card for detection of inducible clindamycin resistance in Staphylococcus spp. J Clin Microbiol (2010) 1.56
Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood (2008) 1.56
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood (2010) 1.51
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica (2012) 1.47
HLA-G: from biology to clinical benefits. Trends Immunol (2008) 1.45
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica (2010) 1.42
CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood (2003) 1.40
Trogocytosis-based generation of suppressive NK cells. EMBO J (2007) 1.40
The 14 bp deletion-insertion polymorphism in the 3' UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol (2003) 1.39
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res (2012) 1.38
HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res (2005) 1.35
ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood (2011) 1.35
HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol (2003) 1.33
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica (2010) 1.32
Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Cell Mol Life Sci (2010) 1.29
In silico analysis of microRNAS targeting the HLA-G 3' untranslated region alleles and haplotypes. Hum Immunol (2009) 1.27
Ciprofloxacin-resistant Shigella sonnei among men who have sex with men, Canada, 2010. Emerg Infect Dis (2011) 1.26
Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis (2005) 1.25
International proficiency study of a consensus L1 PCR assay for the detection and typing of human papillomavirus DNA: evaluation of accuracy and intralaboratory and interlaboratory agreement. J Clin Microbiol (2003) 1.23
CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos (2005) 1.19
Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr (2004) 1.19
vanA-containing Enterococcus faecium susceptible to vancomycin and teicoplanin because of major nucleotide deletions in Tn1546. J Antimicrob Chemother (2011) 1.17
CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica (2005) 1.16
Cereblon expression in multiple myeloma: not ready for prime time. Br J Haematol (2013) 1.15
Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk (2010) 1.15
Prevalence and age distribution of human papillomavirus infection in a population of Inuit women in Nunavik, Quebec. Cancer Epidemiol Biomarkers Prev (2008) 1.14
Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol (2003) 1.13
Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. AIDS (2013) 1.10
Synthetic Plasmodium-like hemozoin activates the immune response: a morphology - function study. PLoS One (2009) 1.10
Polimorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity (2012) 1.09
Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res (2012) 1.08
High expression levels of B lymphocyte stimulator (BLyS) by dendritic cells correlate with HIV-related B-cell disease progression in humans. Blood (2010) 1.07
Human papillomavirus type 33 polymorphisms and high-grade squamous intraepithelial lesions of the uterine cervix. J Infect Dis (2006) 1.07
Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging (2009) 1.07
RREB-1 is a transcriptional repressor of HLA-G. J Immunol (2009) 1.05
HLA-G in cancer: a way to turn off the immune system. Semin Cancer Biol (2003) 1.05
Gene expression profiles in human lymphocytes irradiated in vitro with low doses of gamma rays. Radiat Res (2007) 1.04
Genetic variants in nonclassical major histocompatibility complex class I human leukocyte antigen (HLA)-E and HLA-G molecules are associated with susceptibility to heterosexual acquisition of HIV-1. J Infect Dis (2005) 1.03
Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol (2007) 1.03
Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood (2006) 1.03
HIV infection affects blood myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease. J Infect Dis (2009) 1.02
Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies. Biol Blood Marrow Transplant (2009) 1.01
HLA polymorphisms and cervical human Papillomavirus infection in a cohort of Montreal University students. J Infect Dis (2007) 1.01
Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics (2006) 1.00
APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. AIDS (2006) 1.00
Functionally active HLA-G polymorphisms are associated with the risk of heterosexual HIV-1 infection in African women. AIDS (2004) 0.99
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging (2010) 0.99
213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J Nucl Med (2013) 0.99
Polymorphic sites at the 3' untranslated region of the HLA-G gene are associated with differential hla-g soluble levels in the Brazilian and French population. PLoS One (2013) 0.99
European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist (2012) 0.98
Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go? Semin Hematol (2011) 0.98